TY - JOUR
T1 - Association of polycythemia with outcomes of acute decompensated heart failure
T2 - A matched and weighted cohort analysis
AU - Perets, Snir
AU - Minha, Saar
AU - Maymon, Shiri L.
AU - Kalmanovich, Eran
AU - Moravsky, Gil
AU - Minha, Ido
AU - Grupper, Avishay
AU - Fuchs, Shmuel
AU - Marcus, Gil
N1 - Publisher Copyright:
© 2026 Perets et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2026/4
Y1 - 2026/4
N2 - Aims The prognostic significance of polycythemia in acute decompensated heart failure (ADHF) is unclear. This study aimed to evaluate the clinical profile and prognostic implications of polycythemia compared with anemia and normocythemia in patients hospitalized with ADHF. Materials and methods We retrospectively analyzed adult patients hospitalized with ADHF between 2007 and 2017. Patients were categorized by hemoglobin according to World Health Organization criteria: anemic (<13 g/dL men, < 12 g/dL women), normocythemic, or polycythemic (>18.5 g/dL men, > 16.5 g/dL women). Mahalanobis distance matching (MDM; 1:3:3) balanced baseline characteristics, with outcomes compared for in-hospital mortality, 30-day readmission, and long-term survival. Entropy balancing (EBAL) served as sensitivity analysis in the full cohort. Results Of 8,332 patients, 5,615 (67.4%) were anemic, 2,639 (31.7%) normocythemic, and 78 (0.9%) polycythemic. Polycythemic patients were younger, predominantly male, and more likely to undergo coronary interventions and receive cardioprotective discharge medications. In the matched cohort (N = 546; 234 anemic, 234 normocythemic, 78 polycythemic), in-hospital mortality rates were similar (5.6%, 3.8%, 7.7%; p = 0.381). One-year mortality was highest in anemia (27.4%) vs. normocythemia (17.5%) and polycythemia (19.2%; p = 0.030). Five-year Kaplan–Meier survival was poorest in anemia, with overlapping curves for polycythemia and normocythemia (log-rank p = 0.027). Cox analysis (reference = normocythemia) showed higher mortality with anemia (HR 1.30, 95% CI 1.03–1.63) but not polycythemia (HR 0.90, 95% CI 0.64–1.27). Post-hoc pairwise log-rank tests (Bonferroni-corrected) confirmed no difference between polycythemia and normocythemia. EBAL-weighted analysis yielded consistent results (log-rank p < 0.001; anemia HR 1.76, 95% CI 1.61–1.92; polycythemia HR 1.14, 95% CI 0.83–1.57). Conclusions Polycythemia is rare in hospitalized ADHF and, unlike anemia, is not associated with adverse short- or long-term outcomes.
AB - Aims The prognostic significance of polycythemia in acute decompensated heart failure (ADHF) is unclear. This study aimed to evaluate the clinical profile and prognostic implications of polycythemia compared with anemia and normocythemia in patients hospitalized with ADHF. Materials and methods We retrospectively analyzed adult patients hospitalized with ADHF between 2007 and 2017. Patients were categorized by hemoglobin according to World Health Organization criteria: anemic (<13 g/dL men, < 12 g/dL women), normocythemic, or polycythemic (>18.5 g/dL men, > 16.5 g/dL women). Mahalanobis distance matching (MDM; 1:3:3) balanced baseline characteristics, with outcomes compared for in-hospital mortality, 30-day readmission, and long-term survival. Entropy balancing (EBAL) served as sensitivity analysis in the full cohort. Results Of 8,332 patients, 5,615 (67.4%) were anemic, 2,639 (31.7%) normocythemic, and 78 (0.9%) polycythemic. Polycythemic patients were younger, predominantly male, and more likely to undergo coronary interventions and receive cardioprotective discharge medications. In the matched cohort (N = 546; 234 anemic, 234 normocythemic, 78 polycythemic), in-hospital mortality rates were similar (5.6%, 3.8%, 7.7%; p = 0.381). One-year mortality was highest in anemia (27.4%) vs. normocythemia (17.5%) and polycythemia (19.2%; p = 0.030). Five-year Kaplan–Meier survival was poorest in anemia, with overlapping curves for polycythemia and normocythemia (log-rank p = 0.027). Cox analysis (reference = normocythemia) showed higher mortality with anemia (HR 1.30, 95% CI 1.03–1.63) but not polycythemia (HR 0.90, 95% CI 0.64–1.27). Post-hoc pairwise log-rank tests (Bonferroni-corrected) confirmed no difference between polycythemia and normocythemia. EBAL-weighted analysis yielded consistent results (log-rank p < 0.001; anemia HR 1.76, 95% CI 1.61–1.92; polycythemia HR 1.14, 95% CI 0.83–1.57). Conclusions Polycythemia is rare in hospitalized ADHF and, unlike anemia, is not associated with adverse short- or long-term outcomes.
UR - https://www.scopus.com/pages/publications/105036254525
U2 - 10.1371/journal.pone.0345255
DO - 10.1371/journal.pone.0345255
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 42008464
AN - SCOPUS:105036254525
SN - 1932-6203
VL - 21
JO - PLoS ONE
JF - PLoS ONE
IS - 4 April
M1 - e0345255
ER -